Ayuvis Research Inc.
Fort Worth, TX
- UEI
- E3H4XC65GZU3
- CAGE
- 72E37
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 3500 Camp Bowie Blvd #116j, Fort Worth, TX 76107, USA
- Website
- ayuvis.com
- Founded
- 2014
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
About the company
Ayuvis Research Inc., operating through its Ayuvis Research Division, is a minority-owned small business focused on developing novel therapeutic approaches for neonatal and pediatric respiratory conditions. The company specializes in creating innovative small molecule therapies, particularly targeting bronchopulmonary dysplasia (BPD) in preterm infants. Ayuvis Research has been registered to receive federal awards since February 2014 and holds multiple business classifications, including Minority Owned Business, Self Certified Small Disadvantaged Business, and Economically Disadvantaged Women Small Owned Business. The company's primary focus appears to be on advancing its lead compound, AVR-48, a macrophage modulator designed to prevent and treat BPD, for which there are currently no specific drug therapies available.
Ayuvis Research has received multiple federal grant awards from the National Institutes of Health to support the development of AVR-48. These awards include funding from the National Institute of Child Health and Human Development (NICHD) and the National Heart Lung and Blood Institute (NHLBI). The grants have supported various stages of preclinical and clinical development, including safety studies in animal models, pharmacokinetic studies, and early-phase clinical trials. Specifically, the company has conducted research to demonstrate AVR-48's ability to mitigate inflammation, cell death, and disrupted lung development in mouse and preterm lamb models of BPD. Recent awards are funding a Phase 1 safety and pharmacokinetic study in healthy adult volunteers, followed by a Phase 2a proof-of-concept trial in preterm infants at risk of developing BPD. These studies aim to advance AVR-48 towards clinical development as a potential prophylactic treatment for BPD, addressing a significant unmet medical need in neonatal care.
Quick answers
Is Ayuvis Research Inc. registered in SAM.gov?
Yes. Ayuvis Research Inc.'s SAM.gov registration is active through April 22, 2027.
What is Ayuvis Research Inc.'s most recent federal award?
Ayuvis Research Inc.'s most recent federal grant award is Phase 1 safety, pharmacokinetic study followed by phase 2A proof-of-concept study of AVR-48, a small molecule… (R44HD112276), from National Institute of Child Health and Human Development (NIH), on April 12, 2024.
On GovTribe
See Ayuvis Research Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors